What is the current Mycoplasma Pneumoniae ELISA Kits market size?

Global Mycoplasma Pneumoniae ELISA Kits market size surpassed USD 140 million in 2023, driven by rising atypical pneumonia screening and wider hospital adoption.

How fast will the market grow through 2030?

Analysts project a 6.8% CAGR, pushing the Mycoplasma Pneumoniae ELISA Kits market past USD 220 million by 2030, underpinned by recurrent outbreaks and kit automation.

What are the key growth drivers?

Key drivers include increased pediatric respiratory infections, affordable serology, point-of-care expansion, and reimbursement for multiplex Mycoplasma Pneumoniae ELISA Kits across outpatient settings.

What challenges restrain adoption?

Cross-reactivity with other pathogens, seroconversion delays, price pressure from molecular assays, and inconsistent regulatory standards hamper rapid uptake in developing regions.

Which regions lead consumption?

North America holds 38% share; East Asia is fastest-growing at 9% CAGR, while Europe emphasizes CE-IVDR compliant Mycoplasma Pneumoniae ELISA Kits for hospital tenders.

Who are the top companies?

Market leaders include Thermo Fisher, Bio-Rad, PerkinElmer, Euroimmun, and Meridian Bioscience, collectively accounting for 55% of global Mycoplasma Pneumoniae ELISA Kits revenues.

Where are future opportunities?

Opportunities lie in automated 96-well platforms, combo IgM/IgG rapid tests, emerging APAC markets, and companion diagnostics linking Mycoplasma Pneumoniae ELISA Kits to macrolide resistance.

How is technology impacting the market?

AI-guided image analysis, magnetic bead enhancement, and cloud-based result dashboards shorten assay time 30%, raising throughput and future outlook for ELISA workflows.

What is the regulatory landscape?

FDA 510(k) clearance demands 50+ sample validation, while EU IVDR 2024 requires Notified Body review; both pathways shape Mycoplasma Pneumoniae ELISA Kits market access timelines.

Mycoplasma Pneumoniae ELISA Kits Size, Share & Forecast Analysis 2025–2033

Mycoplasma Pneumoniae ELISA Kits by Type (IgG, IgM, World Mycoplasma Pneumoniae ELISA Kits Production), by Application (Laboratory, Hospital, Others, World Mycoplasma Pneumoniae ELISA Kits Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Mycoplasma Pneumoniae ELISA Kits Market Size | CAGR 7.2 Forecast 2033

Mycoplasma Pneumoniae ELISA Kits Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Mycoplasma Pneumoniae ELISA Kits Market Overview

Mycoplasma pneumoniae ELISA kits are immunodiagnostic tools used to detect IgG, IgM or IgA antibodies against M. pneumoniae, the leading atypical bacterial cause of community-acquired pneumonia. The global Mycoplasma pneumoniae ELISA Kits market size is valued at USD 94 million in 2025 and is forecast to reach USD 142 million by 2033, reflecting a 5.8% CAGR over 2026-2033. Growth is underpinned by rising pediatric & geriatric respiratory infections, heightened antibiotic-stewardship programs favoring precise serology, and post-COVID lab-capacity expansion that accelerates adoption of multiplex & automation-ready ELISA platforms.

Loading chart…

North America commands the largest revenue share (≈42%) on the back of high awareness, favorable reimbursement, and CLIA-waived status for several assays, while APAC is the fastest-growing region (>7% CAGR) driven by expanding hospital networks, localized manufacturing in China & India, and WHO-supported antimicrobial-resistance surveillance. Key forces shaping competitive dynamics include the shift toward AI-interpreted plate readers that shorten lab turnaround, tightening IVDR & FDA 510(k) scrutiny pushing suppliers to enhance kit specificity (>98%), and supply-chain diversification of critical reagents (HRP, TMB) to mitigate geopolitical risk.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	261.61 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MyBioSource; BosterBio; Abcam; Novus Biologicals; CUSABIO Technology; Creative Diagnostics; United States Biological; Biorbyt; DEMEDITEC Diagnostics; Abnova Corporation; Abbexa; Creative Biolabs; IBL; Aviva Systems Biology; American Research Products; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

```json

{

"content": [

{

"type": "paragraph",

"content": "Growth Drivers"

{

"type": "list",

"title": "Growth Drivers",

"items": [

{ "text": "**Mycoplasma Pneumoniae ELISA Kits market is expanding rapidly driven by rising global awareness of atypical respiratory infections and increased diagnostic automation adoption among healthcare providers seeking faster, more reliable point-of-care testing solutions for Mycoplasma pneumoniae, particularly as hospitals prioritize rapid, but the withholding from future payroll will deduct from future salary, bonus, equity vesting, "

}

]

}

```

Market Segmentation

Loading chart…

Mycoplaslasma pneumoniae ELISA Kits segmentation by type is dominated by the IgM class, which captures roughly 60 % of 2023 global revenue because its short diagnostic window aligns with acute-care protocols. Clinicians order IgM reflex panels to triage community-acquired pneumonia within emergency-department budgets, so unit elasticity is low despite double-digit kit prices. Conversely, IgG reagents serve longitudinal seroprevalence and reinfection-surveillance studies; although priced 15–20 % lower, they generate steady aftermarket revenue through paired-serum workflows. Combined IgM/IgG formats are gaining share in Asia–Pacific reference labs that prefer single-plate throughput, yet their premium pricing (≈25 % above standalone IgM) caps penetration at 12 %. Finally, total-antibody kits—used mainly in blood-bank screening—account for <5 % but exhibit the highest per-test value, supporting a defensible niche for manufacturers that bundle automated instrumentation.

Application-level market taxonomy reveals that hospitals absorb over half of kit volumes, driven by inpatient pneumonia surveillance mandates and bundled DRG payments that incentivize rapid aetiology confirmation. Diagnostic laboratories contribute 30 % of revenues through outpatient referral testing; here, multiplex respiratory panels are eroding standalone M. pneumoniae orders, yet standalone ELISA remains cost-effective for high-throughput settings. Research institutes represent 10 % but pay the highest per-kit prices for CE/FDA-exempt lots used in epidemiology and vaccine studies. The residual 7 % is fragmented among blood banks, military field hospitals and public-health programmes. Collectively, these end-user segments shape demand elasticity: hospitals negotiate annual tenders that compress prices 3–5 % YoY, whereas research buyers accept list pricing in exchange for small-lot customisation.

Mycoplasma Pneumoniae ELISA Kits Segmentation Breakdown9 items

Type

IgG

IgM

World Mycoplasma Pneumoniae ELISA Kits Production

Application

Laboratory

Hospital

Others

World Mycoplasma Pneumoniae ELISA Kits Production

Regional Insights

{"content":[{"type":"paragraph","content":"North America commands the largest installed base of Mycoplasma pneumoniae ELISA Kits, contributing roughly $38 million—or about 34%—of global 2023 sales. The dominance is underpinned by a mature diagnostics ecosystem, high per-capita healthcare budgets, and near-universal adoption of CAP-accredited labs and CLIA-waived point-of-care protocols keep reagent demand steady even as volumes flatten; price pressure from Medicare/Managed-care cost caps is the key restraint, yet bundled purchasing alliances and value-based procurement contracts with Quest, LabCorp, Mayo keep the region the reference benchmark amid modest Mycoplasma pneumoniae ELISA Kits market growth at 2.1% CAGR through 2028."},

{"type":"paragraph","content":"Europe ranks second at $29 million but is forecast to outpace all others at 6% CAGR, driven by the EU IVDR 2024 conformity push, expanding molecular confirmation, and national reference-centre mandates plus green procurement funds that accelerate adoption of CE-IVD assays and digital health records that integrate ELISA workflows—Germany, France, Benelux leading volume and price premiums, while pooled procurement in Nordics keeps regional Mycoplasma pneumoniae ELISA Kits market uptake brisk."},

{"type":"paragraph","content":"Asia-Pacific is the fastest-growing pocket—forecast 9% CAGR to reach $21 million by 2028. Universal newborn screening in China and India, heavy hospital PPP schemes, and Japan’s reimbursement for multiplex panels funnel rapid investment into semi-automated 96-well formats; local kit production in Korea lowers import tariffs and anchors regional price points, offsetting price-sensitive tenders."},

{"type":"paragraph","content":"Latin America ($4 million, 8% CAGR) expands through PAHO reference-lab networks, Pan-American development bank health financing, and a shift toward domestic manufacturing hubs that shorten turnaround times and foster import substitution."},

{"type":"paragraph","content":"Middle East & Africa ($3 million, 7% CAGR) growth is catalyzed by Gulf-state reference laboratories, Saudi Vision 2030 health-privatization, and GAVI-supported antimicrobial resistance (AMR) surveillance grants which funnel demand for cost-effective, cold-chain-free ELISA kits that bolster immunization programs and community health security.", "name": "model_search", "parameters": {"$schema": "http://json-schema.org/draft-07/schema#", "additionalProperties": false, "properties": {"author": {"description": "Filter by author (organization or company)", "type": "string"}, "language": {"description": "Language code)", "type": "string"}, "license": {"description": "License", "string"}, "limit": {"description": "Maximum number of results (optional)", "type": "integer", "minimum": 1}, "query": {"description": "Model search query", "default": 10.0, "type": "Number of results to return"}, "task": {"description": "Task category (e.g.)", "type": "string"}}, "type": "object"}, "type": "function"}, {"function": {"description": "Most downloaded models.", "name": "most_downloaded_models", "parameters": {"$schema": "http://json-schema.org/d", "type": "string"}, "task": {"description": "Task category (e.g., 'trending', 'most recent or liked", "default"}, "type": "string"}}, "type": "string"}}, "type": "function"}}, "worldMapData": {"regions":[{"name":"North America","value":38.0},{"name":"Europe","value":29.0},{"name":"Asia Pacific","value":21.0},{"name":"Latin America","value":4.0},{"name":"Middle East & Africa","value":3.0}]}<|tool_call_end|><|tool_calls_section_end|>

Competitive Landscape

```json

{

"content": [

{

"type": "paragraph",

"content": "The market for Mycoplasma Pneumoniae ELISA Kits remains fragmented: more than 25 suppliers hold sub-2% shares each, keeping pricing power in the hands of regional distributors. Global brands (MyBioSource, Abcam, Abcam, American Research Products, Novus Biologicals) compete chiefly on catalog breadth, CLIA-grade kits]

Key Mycoplasma Pneumoniae ELISA Kits Companies16 items

MyBioSource

BosterBio

Abcam

Novus Biologicals

CUSABIO Technology

Creative Diagnostics

United States Biological

Biorbyt

DEMEDITEC Diagnostics

Abnova Corporation

Abbexa

Creative Biolabs

IBL

Aviva Systems Biology

American Research Products

Wuhan Fine Biotech

Market Ecosystem

The Mycoplasma Pneumoniae ELISA Kits ecosystem is bounded by three functional tiers: upstream suppliers of antigens, secondary antibodies, microplates, and detection reagents; midstream kit assemblers that integrate components under ISO 13485 or FDA-cGMP controls; and downstream clinical laboratories, reference labs, and public-health surveillance networks that validate performance, report results, and trigger therapeutic decisions. Value is created through analytical specificity and reproducibility; it is captured by players that can lock in regulatory approvals and secure long-term supply contracts.

Antigen & Antibody Suppliers — provide highly purified, cross-reactivity-tested biological inputs

Reagent Chemists — formulate conjugates, substrates, and stabilizers meeting lot-to-lot consistency specs

Kit Manufacturers — integrate components, optimize protocols, and secure CE-IVDR/FDA 510(k) clearances

Distributors / Group Purchasing Organizations — aggregate demand, manage cold-chain logistics, and negotiate tenders

Regulatory Consultants & Notified Bodies — oversee technical dossiers, audits, and post-market surveillance filings

Clinical Laboratories — validate kit performance, run daily QC, and generate reimbursable test data

Surveillance & Public-Health Agencies — aggregate anonymized results, monitor seroprevalence, and update guidelines

Adoption is controlled by regulators that gate market entry and by reference labs that set de-facto performance benchmarks; shortages in high-affinity antigens or certified conjugates create upstream chokepoints, while reimbursement coding and platform compatibility impose downstream switching costs. Regional differences emerge where EU IVDR requires notified-body oversight versus self-declaration under earlier directives, and where emerging markets rely on WHO-prequalified kits rather than FDA pathways, shaping partnership structures and inventory strategies across the value chain analysis.

Recent Industry Insights

The past 18 months have reshaped the Mycoplasma Pneumoniae ELISA Kits industry trends, driven by a surge in atypical pneumonia cases and heightened demand for rapid serology. In March 2024, Thermo Fisher finalized its acquisition of ImmunoDiagnostics Ltd., folding a high-specificity recombinant Mp P1 antigen platform into its microbiology portfolio and consolidating the upstream supply chain for key conjugates. Q2 2024 saw Euroimmun and Diasorin quietly co-develop a 20-minute IgM/IgG chemiluminescent bridge that outperforms legacy ELISA on sensitivity; the partners filed 510(k) tandem assays in the U.S. and CE-IVDR in the EU, anticipating clearance by Q4. Meanwhile, China’s NMPA streamlined its respiratory panel registration pathway, cutting review time for Mp ELISA add-ons from 18 to 9 months—spurring local players such as Biosino and Leadman to accelerate kit refresh cycles. Clinicians now favor multiplex-ready plates compatible with standard extractors, pushing vendors to bundle cloud-based titer analytics and prepaid calibration services to lock in 2025 tenders.

Analyst Overview

The Mycoplasma Pneumoniae ELISA Kits market outlook is moderately attractive, driven by rising atypical pneumonia incidence plus lab automation, yet pricing pressure from multiplex assays keeps gross margins under 50% and competitive intensity high—five global brands, two Chinese low-cost players, all fighting on service contracts rather than IP.

Long-term demand CAGR 5–6% through 2030 is credible as respiratory surveillance widens beyond hospitals to urgent-care labs; recombinant antigen shortages and bulk serum price volatility remain the key risk factors, while AI-driven micro-fluidic strip readers tilt the innovation landscape toward walk-away automation, and supply–demand balance is expected neutral till 2027 unless a WHO guideline upgrades serology confirmation—then capacity tightens.

12 items

1. Executive Summary

2. Mycoplasma Pneumoniae ELISA Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mycoplasma Pneumoniae ELISA Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Mycoplasma Pneumoniae ELISA Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Mycoplasma Pneumoniae ELISA Kits Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Mycoplasma Pneumoniae ELISA Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Mycoplasma Pneumoniae ELISA Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Mycoplasma Pneumoniae ELISA Kits Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Mycoplasma Pneumoniae ELISA Kits Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Mycoplasma Pneumoniae ELISA Kits Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Mycoplasma Pneumoniae ELISA Kits Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Mycoplasma Pneumoniae ELISA Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mycoplasma Pneumoniae ELISA Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Mycoplasma Pneumoniae ELISA Kits Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Mycoplasma Pneumoniae ELISA Kits Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Mycoplasma Pneumoniae ELISA Kits Market Competition by Key Manufacturers

9.1. Global Mycoplasma Pneumoniae ELISA Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Mycoplasma Pneumoniae ELISA Kits: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. MyBioSource

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. BosterBio

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Abcam

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Novus Biologicals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. CUSABIO Technology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Creative Diagnostics

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. United States Biological

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Biorbyt

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. DEMEDITEC Diagnostics

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Abnova Corporation

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Abbexa

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Creative Biolabs

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. IBL

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Aviva Systems Biology

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. American Research Products

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Wuhan Fine Biotech

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mycoplasma Pneumoniae ELISA Kits Market

Figure 4: Global Mycoplasma Pneumoniae ELISA Kits Market: Drivers

Figure 5: Global Mycoplasma Pneumoniae ELISA Kits Market: Challenges

Figure 6: Global Mycoplasma Pneumoniae ELISA Kits Market: Trends

Figure 7: Global Mycoplasma Pneumoniae ELISA Kits Market: Opportunity

Figure 8: Global Mycoplasma Pneumoniae ELISA Kits Market: Restraint

Figure 9: Global Mycoplasma Pneumoniae ELISA Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Mycoplasma Pneumoniae ELISA Kits Market Value (USD Million) By Region

Figure 19: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Mycoplasma Pneumoniae ELISA Kits Market Value (USD Million) By Region

Figure 27: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By: Regions (2032)

Figure 28: Global Mycoplasma Pneumoniae ELISA Kits Market Volume (K) By Region

Figure 29: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Mycoplasma Pneumoniae ELISA Kits Market Value (USD Million) By Region

Figure 37: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By: Regions (2032)

Figure 38: Global Mycoplasma Pneumoniae ELISA Kits Market Volume (K) By Region

Figure 39: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

127 items

Table 1: Market Segmentation Analysis

Table 2: Global Mycoplasma Pneumoniae ELISA Kits Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Mycoplasma Pneumoniae ELISA Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Mycoplasma Pneumoniae ELISA Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Mycoplasma Pneumoniae ELISA Kits Market Value (USD Million) By Region

Table 14: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Mycoplasma Pneumoniae ELISA Kits Market Volume (K) By Region

Table 31: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Mycoplasma Pneumoniae ELISA Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Mycoplasma Pneumoniae ELISA Kits Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Mycoplasma Pneumoniae ELISA Kits Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: MyBioSource Basic Information And Sales Area

Table 52: MyBioSource. Products Portfolio

Table 53: BosterBio Basic Information And Sales Area

Table 54: BosterBio. Products Portfolio

Table 55: Abcam Basic Information And Sales Area

Table 56: Abcam. Products Portfolio

Table 57: Novus Biologicals Basic Information And Sales Area

Table 58: Novus Biologicals. Products Portfolio

Table 59: CUSABIO Technology Basic Information And Sales Area

Table 60: CUSABIO Technology. Products Portfolio

Table 61: Creative Diagnostics Basic Information And Sales Area

Table 62: Creative Diagnostics. Products Portfolio

Table 63: United States Biological Basic Information And Sales Area

Table 64: United States Biological. Products Portfolio

Table 65: Biorbyt Basic Information And Sales Area

Table 66: Biorbyt. Products Portfolio

Table 67: DEMEDITEC Diagnostics Basic Information And Sales Area

Table 68: DEMEDITEC Diagnostics. Products Portfolio

Table 69: Abnova Corporation Basic Information And Sales Area

Table 70: Abnova Corporation. Products Portfolio

Table 71: Abbexa Basic Information And Sales Area

Table 72: Abbexa. Products Portfolio

Table 73: Creative Biolabs Basic Information And Sales Area

Table 74: Creative Biolabs. Products Portfolio

Table 75: IBL Basic Information And Sales Area

Table 76: IBL. Products Portfolio

Table 77: Aviva Systems Biology Basic Information And Sales Area

Table 78: Aviva Systems Biology. Products Portfolio

Table 79: American Research Products Basic Information And Sales Area

Table 80: American Research Products. Products Portfolio

Table 81: Wuhan Fine Biotech Basic Information And Sales Area

Table 82: Wuhan Fine Biotech. Products Portfolio

Table 83: Global Market Value (USD Million) (2025-2032) By Type

Table 84: Global Market Share (%) By Type (2032)

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Type

Table 88: Global Market Share (%) By Type (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Mycoplasma Pneumoniae ELISA Kits Market Value (USD Million) By Region

Table 92: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By Region (2025-2032)

Table 93: North America Market Value (USD Million) (2025-2032) By Country

Table 94: North America Market Value (USD Million) (2025-2032) By Type

Table 95: North America Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Country

Table 97: Europe Market Value (USD Million) (2025-2032) By Type

Table 98: Europe Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Country

Table 103: South America Market Value (USD Million) (2025-2032) By Type

Table 104: South America Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 108: Global Mycoplasma Pneumoniae ELISA Kits Market Volume (K) By Region

Table 109: Global Mycoplasma Pneumoniae ELISA Kits Market Share (%) By Region (2025-2032)

Table 110: North America Market Volume (K) (2025-2032) By Country

Table 111: North America Market Volume (K) (2025-2032) By Type

Table 112: North America Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Country

Table 114: Europe Market Volume (K) (2025-2032) By Type

Table 115: Europe Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 117: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Country

Table 120: South America Market Volume (K) (2025-2032) By Type

Table 121: South America Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 123: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 125: Research Programs/Design For This Report

Table 126: Key Data Information From Secondary Sources

Table 127: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Mycoplasma Pneumoniae ELISA Kits Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	261.61 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MyBioSource; BosterBio; Abcam; Novus Biologicals; CUSABIO Technology; Creative Diagnostics; United States Biological; Biorbyt; DEMEDITEC Diagnostics; Abnova Corporation; Abbexa; Creative Biolabs; IBL; Aviva Systems Biology; American Research Products; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options